{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:46:31Z","timestamp":1768931191078,"version":"3.49.0"},"publisher-location":"Singapore","reference-count":151,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811043031","type":"print"},{"value":"9789811043048","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-981-10-4304-8_8","type":"book-chapter","created":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T15:01:10Z","timestamp":1509634870000},"page":"103-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy"],"prefix":"10.1007","author":[{"given":"Elena","family":"Cavarretta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Mastroiacovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annik","family":"Lupieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Frati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Peruzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,3]]},"reference":[{"issue":"11","key":"8_CR1","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11):e442","journal-title":"PLoS Med"},{"issue":"2","key":"8_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","volume":"103","author":"AB Mariotto","year":"2011","unstructured":"Mariotto AB, Yabroff KR, Shao Y et al (2011) Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103(2):117\u2013128","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"8_CR3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.healun.2012.03.018","volume":"31","author":"GH Oliveira","year":"2012","unstructured":"Oliveira GH, Hardaway BW, Kucheryavaya AY et al (2012) Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant 31(8):805\u2013810","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"8_CR4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.repc.2012.11.002","volume":"32","author":"R Ad\u00e3o","year":"2013","unstructured":"Ad\u00e3o R, de Keulenaer G, Leite-Moreira A et al (2013) Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies. Rev Port Cardiol 32(5):395\u2013409","journal-title":"Rev Port Cardiol"},{"issue":"4","key":"8_CR5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/157340311799960681","volume":"7","author":"A Saidi","year":"2011","unstructured":"Saidi A, Alharethi R (2011) Management of chemotherapy induced cardiomyopathy. Curr Cardiol Rev 7(4):245\u2013249","journal-title":"Curr Cardiol Rev"},{"issue":"6","key":"8_CR6","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","volume":"52","author":"Y Octavia","year":"2012","unstructured":"Octavia Y, Tocchetti CG, Gabrielson KL et al (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52(6):1213\u20131225","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"8_CR7","doi-asserted-by":"crossref","first-page":"H37","DOI":"10.1152\/ajpheart.01057.2004","volume":"289","author":"M Tokarska-Schlattner","year":"2005","unstructured":"Tokarska-Schlattner M, Zaugg M, da Silva R et al (2005) Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol 289(1):H37\u2013H47","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"8_CR8","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1074\/jbc.M308033200","volume":"279","author":"CC Lim","year":"2004","unstructured":"Lim CC, Zuppinger C, Guo X et al (2004) Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279(9):8290\u20138299","journal-title":"J Biol Chem"},{"issue":"2","key":"8_CR9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.109.895771","volume":"121","author":"A Angelis De","year":"2010","unstructured":"De Angelis A, Piegari E, Cappetta D et al (2010) Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121(2):276\u2013292","journal-title":"Circulation"},{"issue":"3","key":"8_CR10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.18433\/J3JS5R","volume":"19","author":"SA Kouzi","year":"2016","unstructured":"Kouzi SA, Uddin MN (2016) Aerobic exercise training as a potential cardioprotective strategy to attenuate doxorubicin-induced cardiotoxicity. J Pharm Pharm Sci 19(3):399\u2013410","journal-title":"J Pharm Pharm Sci"},{"issue":"4","key":"8_CR11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.21341","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano G, Cardinale D, Dent S et al (2016) Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin 66(4):309\u2013325","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"8_CR12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","volume":"12","author":"MS Ewer","year":"2015","unstructured":"Ewer MS, Ewer SM (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12(9):547\u2013558","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"8_CR13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","volume":"57","author":"DA Gewirtz","year":"1999","unstructured":"Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57(7):727\u2013741","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"8_CR14","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","volume":"90","author":"RM Damiani","year":"2016","unstructured":"Damiani RM, Moura DJ, Viau CM et al (2016) Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol 90(9):2063\u20132076","journal-title":"Arch Toxicol"},{"issue":"44","key":"8_CR15","doi-asserted-by":"crossref","first-page":"e5195","DOI":"10.1097\/MD.0000000000005195","volume":"95","author":"Z Jawa","year":"2016","unstructured":"Jawa Z, Perez RM, Garlie L et al (2016) Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Medicine (Baltimore) 95(44):e5195","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"8_CR16","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/sj.bjc.6600346","volume":"86","author":"T Nousiainen","year":"2002","unstructured":"Nousiainen T, Jantunen E, Vanninen E et al (2002) Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 86(11):1697\u20131700","journal-title":"Br J Cancer"},{"issue":"5","key":"8_CR17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ehjci\/jev024","volume":"16","author":"P Lancellotti","year":"2015","unstructured":"Lancellotti P, Anker SD, Donal E et al (2015) EACVI\/HFA cardiac oncology toxicity registry in breast cancer patients: rationale, study design, and methodology (EACVI\/HFA COT Registry)\u00a0\u2013 EURObservational research program of the European society of cardiology. Eur Heart J Cardiovasc Imaging 16(5):466\u2013470","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"8_CR18","first-page":"54","volume":"71","author":"DL Li","year":"2014","unstructured":"Li DL, Hill JA (2014) Cardiomyocyte autophagy and cancer chemotherapy. J Mol Cell Cardiol 71(6):54\u201361","journal-title":"J Mol Cell Cardiol"},{"issue":"11","key":"8_CR19","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11):2869\u20132879","journal-title":"Cancer"},{"issue":"2","key":"8_CR20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","volume":"53","author":"DB Sawyer","year":"2010","unstructured":"Sawyer DB, Peng X, Chen B et al (2010) Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 53(2):105\u2013113","journal-title":"Prog Cardiovasc Dis"},{"issue":"22","key":"8_CR21","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1158\/0008-5472.CAN-10-2664","volume":"70","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, McLaughlin D, Robinson E et al (2010) Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res 70(22):9287\u20139297","journal-title":"Cancer Res"},{"key":"8_CR22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mad.2016.05.004","volume":"159","author":"E Falco De","year":"2016","unstructured":"De Falco E, Carnevale R, Pagano F et al (2016) Role of NOX2 in mediating doxorubicin-induced senescence in human endothelial progenitor cells. Mech Ageing Dev 159:37\u201343","journal-title":"Mech Ageing Dev"},{"issue":"7","key":"8_CR23","first-page":"242180","volume":"2014","author":"R Carnevale","year":"2014","unstructured":"Carnevale R, Biondi-Zoccai G, Peruzzi M et al (2014) New insights into the steen solution properties: breakthrough in antioxidant effects via NOX2 downregulation. Oxidative Med Cell Longev 2014(7):242180","journal-title":"Oxidative Med Cell Longev"},{"issue":"6","key":"8_CR24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00000421-198212000-00015","volume":"5","author":"AR Dresdale","year":"1982","unstructured":"Dresdale AR, Barr LH, Bonow RO et al (1982) Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. Am J Clin Oncol 5(6):657\u2013663","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"8_CR25","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T et al (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18(11):1639\u20131642","journal-title":"Nat Med"},{"issue":"1","key":"8_CR26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/clpt.2013.201","volume":"95","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ET (2014) Topoisomerase 2\u03b2: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 95(1):45\u201352","journal-title":"Clin Pharmacol Ther"},{"issue":"18","key":"8_CR27","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","volume":"67","author":"YL Lyu","year":"2007","unstructured":"Lyu YL, Kerrigan JE, Lin CP et al (2007) Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67(18):8839\u20138846","journal-title":"Cancer Res"},{"issue":"9","key":"8_CR28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ET (2014) Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64(9):938\u2013945","journal-title":"J Am Coll Cardiol"},{"key":"8_CR29","doi-asserted-by":"crossref","first-page":"210934","DOI":"10.1155\/2014\/210934","volume":"2014","author":"Y Ikeda","year":"2014","unstructured":"Ikeda Y, Sciarretta S, Nagarajan N et al (2014) New insights into the role of mitochondrial dynamics and autophagy during oxidative stress and aging in the heart. Oxidative Med Cell Longev 2014:210934","journal-title":"Oxidative Med Cell Longev"},{"key":"8_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2017.01.007","volume":"104","author":"JJ Bartlett","year":"2017","unstructured":"Bartlett JJ, Trivedi PC, Pulinilkunnil T (2017) Autophagic dysregulation in doxorubicin cardiomyopathy. J Mol Cell Cardiol 104:1\u20138","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"8_CR31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.celrep.2015.03.010","volume":"11","author":"S Sciarretta","year":"2015","unstructured":"Sciarretta S, Zhai P, Maejima Y et al (2015) mTORC2 regulates cardiac response to stress by inhibiting MST1. Cell Rep 11(1):125\u2013136","journal-title":"Cell Rep"},{"issue":"17","key":"8_CR32","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1161\/CIRCULATIONAHA.115.017443","volume":"133","author":"DL Li","year":"2016","unstructured":"Li DL, Wang ZV, Ding G et al (2016) Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification. Circulation 133(17):1668\u20131687","journal-title":"Circulation"},{"issue":"21","key":"8_CR33","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1042\/BCJ20160385","volume":"473","author":"JJ Bartlett","year":"2016","unstructured":"Bartlett JJ, Trivedi PC, Yeung P et al (2016) Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy. Biochem J 473(21):3769\u20133789","journal-title":"Biochem J"},{"issue":"21","key":"8_CR34","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.jacc.2014.01.050","volume":"63","author":"G Condorelli","year":"2014","unstructured":"Condorelli G, Latronico MV, Cavarretta E (2014) microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol 63(21):2177\u20132187","journal-title":"J Am Coll Cardiol"},{"key":"8_CR35","doi-asserted-by":"crossref","first-page":"2150763","DOI":"10.1155\/2016\/2150763","volume":"2016","author":"E Cavarretta","year":"2016","unstructured":"Cavarretta E, Frati G (2016) MicroRNAs in coronary heart disease: ready to enter the clinical arena? Biomed Res Int 2016:2150763","journal-title":"Biomed Res Int"},{"issue":"44","key":"8_CR36","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1093\/eurheartj\/eht032","volume":"34","author":"E Cavarretta","year":"2013","unstructured":"Cavarretta E, Chiariello GA, Condorelli G (2013) Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra. Eur Heart J 34(44):3400\u20133402","journal-title":"Eur Heart J"},{"issue":"9","key":"8_CR37","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jacc.2013.09.041","volume":"63","author":"R Roncarati","year":"2014","unstructured":"Roncarati R, Viviani Anselmi C, Losi MA et al (2014) Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 63(9):920\u2013927","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"8_CR38","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/eurheartj\/ehv184","volume":"36","author":"E Cavarretta","year":"2015","unstructured":"Cavarretta E, Condorelli G (2015) miR-21 and cardiac fibrosis: another brick in the wall? Eur Heart J 36(32):2139\u20132141","journal-title":"Eur Heart J"},{"issue":"2","key":"8_CR39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/ATVBAHA.111.242008","volume":"32","author":"E Cavarretta","year":"2012","unstructured":"Cavarretta E, Latronico MV, Condorelli G (2012) Endothelial-to-mesenchymal transition and microRNA-21: the game is on again. Arterioscler Thromb Vasc Biol 32(2):165\u2013166","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"8_CR40","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/cvr\/cvq148","volume":"87","author":"T Horie","year":"2010","unstructured":"Horie T, Ono K, Nishi H et al (2010) Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 87(4):656\u2013664","journal-title":"Cardiovasc Res"},{"issue":"7","key":"8_CR41","doi-asserted-by":"crossref","first-page":"e40395","DOI":"10.1371\/journal.pone.0040395","volume":"7","author":"C Vacchi-Suzzi","year":"2012","unstructured":"Vacchi-Suzzi C, Bauer Y, Berridge BR et al (2012) Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PLoS One 7(7):e40395","journal-title":"PLoS One"},{"key":"8_CR42","doi-asserted-by":"crossref","first-page":"e1754","DOI":"10.1038\/cddis.2015.89","volume":"6","author":"L Roca-Alonso","year":"2015","unstructured":"Roca-Alonso L, Castellano L, Mills A et al (2015) Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in \u03b2-adrenergic signaling and enhances apoptosis. Cell Death Dis 6:e1754","journal-title":"Cell Death Dis"},{"issue":"13","key":"8_CR43","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/01.CIR.98.13.1329","volume":"98","author":"C Communal","year":"1998","unstructured":"Communal C, Singh K, Pimentel DR et al (1998) Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 98(13):1329\u20131334","journal-title":"Circulation"},{"key":"8_CR44","doi-asserted-by":"crossref","first-page":"36774","DOI":"10.1038\/srep36774","volume":"6","author":"I Chimenti","year":"2016","unstructured":"Chimenti I, Pagano F, Cavarretta E et al (2016) \u0392-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells. Sci Rep 6:36774","journal-title":"Sci Rep"},{"issue":"7","key":"8_CR45","first-page":"2862","volume":"8","author":"J Zhang","year":"2016","unstructured":"Zhang J, Cui X, Yan Y et al (2016) Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity. Am J Transl Res 8(7):2862\u20132875","journal-title":"Am J Transl Res"},{"issue":"3","key":"8_CR46","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ijcard.2012.10.079","volume":"167","author":"M Lotrionte","year":"2013","unstructured":"Lotrionte M, Palazzoni G, Abbate A et al (2013) Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. Int J Cardiol 167(3):1055\u20131057","journal-title":"Int J Cardiol"},{"key":"8_CR47","first-page":"CD005006","volume":"3","author":"EC Dalen van","year":"2010","unstructured":"van Dalen EC, Michiels EM, Caron HN et al (2010) Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 3:CD005006","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"8_CR48","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","volume":"15","author":"SM Swain","year":"1997","unstructured":"Swain SM, Whaley FS, Gerber MC et al (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15(4):1333\u20131340","journal-title":"J Clin Oncol"},{"issue":"17","key":"8_CR49","doi-asserted-by":"crossref","first-page":"10261","DOI":"10.1074\/jbc.273.17.10261","volume":"273","author":"YY Zhao","year":"1998","unstructured":"Zhao YY, Sawyer DR, Baliga RR et al (1998) Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273(17):10261\u201310269","journal-title":"J Biol Chem"},{"issue":"1","key":"8_CR50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1023\/B:BREA.0000003916.39959.73","volume":"82","author":"IB Fuchs","year":"2003","unstructured":"Fuchs IB, Landt S, Bueler H et al (2003) Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Breast Cancer Res Treat 82(1):23\u201328","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"8_CR51","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cell.2009.04.060","volume":"138","author":"K Bersell","year":"2009","unstructured":"Bersell K, Arab S, Haring B et al (2009) Neuregulin1\/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138(2):257\u2013270","journal-title":"Cell"},{"issue":"2","key":"8_CR52","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-012-2103-8","volume":"134","author":"C Fedele","year":"2012","unstructured":"Fedele C, Riccio G, Malara AE et al (2012) Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treat 134(2):595\u2013602","journal-title":"Breast Cancer Res Treat"},{"issue":"1 Suppl 3","key":"8_CR53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0093-7754(01)90189-7","volume":"28","author":"JA Sparano","year":"2001","unstructured":"Sparano JA (2001) Cardiac toxicity of trastuzumab (herceptin): implications for the design of adjuvant trials. Semin Oncol 28(1 Suppl 3):20\u201327","journal-title":"Semin Oncol"},{"issue":"6","key":"8_CR54","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10741-015-9502-y","volume":"20","author":"AY Higgins","year":"2015","unstructured":"Higgins AY, O\u2019Halloran TD, Chang JD (2015) Chemotherapy-induced cardiomyopathy. Heart Fail Rev 20(6):721\u2013730","journal-title":"Heart Fail Rev"},{"issue":"5","key":"8_CR55","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1634\/theoncologist.2015-0424","volume":"21","author":"HD Long","year":"2016","unstructured":"Long HD, Lin YE, Zhang JJ et al (2016) Risk of congestive heart failure in early breast cancer patients undergoing adjuvant treatment with trastuzumab: a meta-analysis. Oncologist 21(5):547\u2013554","journal-title":"Oncologist"},{"issue":"14","key":"8_CR56","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.ejca.2007.06.024","volume":"43","author":"MA Korte de","year":"2007","unstructured":"de Korte MA, de Vries EG, Lub-de Hooge MN et al (2007) 111 Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 43(14):2046\u20132051","journal-title":"Eur J Cancer"},{"issue":"10","key":"8_CR57","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","volume":"7","author":"MS Ewer","year":"2010","unstructured":"Ewer MS, Ewer SM (2010) Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 7(10):564\u2013575","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"8_CR58","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","volume":"37","author":"T Chen","year":"2011","unstructured":"Chen T, Xu T, Li Y et al (2011) Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev 37(4):312\u2013320","journal-title":"Cancer Treat Rev"},{"key":"8_CR59","doi-asserted-by":"crossref","unstructured":"Madeddu C, Deidda M, Piras A, et al (2016) Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. J Cardiovasc Med (Hagerstown) 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e12-e18","DOI":"10.2459\/JCM.0000000000000376"},{"issue":"1","key":"8_CR60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","volume":"102","author":"A Albini","year":"2010","unstructured":"Albini A, Pennesi G, Donatelli F et al (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102(1):14\u201325","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"8_CR61","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.taap.2015.03.029","volume":"285","author":"DJ Conklin","year":"2015","unstructured":"Conklin DJ, Haberzettl P, Jagatheesan G et al (2015) Glutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice. Toxicol Appl Pharmacol 285(2):136\u2013148","journal-title":"Toxicol Appl Pharmacol"},{"issue":"24","key":"8_CR62","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ET Yeh","year":"2009","unstructured":"Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53(24):2231\u20132247","journal-title":"J Am Coll Cardiol"},{"issue":"6 Pt 1","key":"8_CR63","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0022-5347(01)62232-8","volume":"160","author":"PM Czaykowski","year":"1998","unstructured":"Czaykowski PM, Moore MJ, Tannock IF (1998) High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 160(6 Pt 1):2021\u20132024","journal-title":"J Urol"},{"issue":"1","key":"8_CR64","first-page":"247","volume":"23","author":"J Nuver","year":"2010","unstructured":"Nuver J, De Haas EC, Van Zweeden M et al (2010) Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 23(1):247\u2013253","journal-title":"Oncol Rep"},{"issue":"5","key":"8_CR65","first-page":"586","volume":"80","author":"D Ai","year":"2014","unstructured":"Ai D, Banchs J, Owusu-Agyemang P et al (2014) Chemotherapy-induced cardiovascular toxicity: beyond anthracyclines. Minerva Anestesiol 80(5):586\u2013594","journal-title":"Minerva Anestesiol"},{"issue":"1","key":"8_CR66","doi-asserted-by":"crossref","first-page":"e000472","DOI":"10.1161\/JAHA.113.000472","volume":"3","author":"G Ezaz","year":"2014","unstructured":"Ezaz G, Long JB, Gross CP et al (2014) Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 3(1):e000472","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"8_CR67","first-page":"250","volume":"16","author":"J Domercant","year":"2016","unstructured":"Domercant J, Polin N, Jahangir E (2016) Cardio-oncology: a focused review of anthracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management. Ochsner J 16(3):250\u2013256","journal-title":"Ochsner J"},{"issue":"12","key":"8_CR68","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/clc.20823","volume":"33","author":"RA Hong","year":"2010","unstructured":"Hong RA, Iimura T, Sumida KN et al (2010) Cardio-oncology\/Onco-cardiology. Clin Cardiol 33(12):733\u2013737","journal-title":"Clin Cardiol"},{"issue":"5","key":"8_CR69","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2014.56.1373","volume":"33","author":"EJ Chow","year":"2015","unstructured":"Chow EJ, Chen Y, Kremer LC et al (2015) Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 33(5):394\u2013402","journal-title":"J Clin Oncol"},{"issue":"12","key":"8_CR70","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1016\/S1470-2045(14)71031-9","volume":"15","author":"A Rahman","year":"2014","unstructured":"Rahman A (2014) Prediction model for heart failure in childhood cancer survivors. Lancet Oncol 15(12):e537","journal-title":"Lancet Oncol"},{"issue":"12","key":"8_CR71","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","volume":"112","author":"M Lotrionte","year":"2013","unstructured":"Lotrionte M, Biondi-Zoccai G, Abbate A et al (2013) Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 112(12):1980\u20131984","journal-title":"Am J Cardiol"},{"issue":"12","key":"8_CR72","doi-asserted-by":"crossref","first-page":"e0165262","DOI":"10.1371\/journal.pone.0165262","volume":"11","author":"P Kotwinski","year":"2016","unstructured":"Kotwinski P, Smith G, Cooper J et\u00a0al (2016) Body surface area and baseline blood pressure predict subclinical anthracycline cardiotoxicity in women treated for early breast cancer. PLoS One 11(12):e0165262","journal-title":"PLoS One"},{"issue":"2","key":"8_CR73","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","volume":"96","author":"SS Legha","year":"1982","unstructured":"Legha SS, Benjamin RS, Mackay B et al (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96(2):133\u2013139","journal-title":"Ann Intern Med"},{"issue":"23","key":"8_CR74","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 61(23):2355\u20132362","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"8_CR75","first-page":"9","volume":"19","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 19(36):9","journal-title":"Eur Heart J"},{"issue":"3","key":"8_CR76","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00268-012-1874-8","volume":"37","author":"E Cavarretta","year":"2013","unstructured":"Cavarretta E, Casella G, Cal\u00ec B et al (2013) Cardiac remodeling in obese patients after laparoscopic sleeve gastrectomy. World J Surg 37(3):565\u2013572","journal-title":"World J Surg"},{"issue":"6","key":"8_CR77","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.athoracsur.2006.04.087","volume":"82","author":"S Castro De","year":"2006","unstructured":"De Castro S, Salandin V, Cavarretta E et al (2006) Epicardial real-time three-dimensional echocardiography in cardiac surgery: a preliminary experience. Ann Thorac Surg 82(6):2254\u20132259","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"8_CR78","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/hrt.2005.069401","volume":"92","author":"S Castro De","year":"2006","unstructured":"De Castro S, Pelliccia A, Caselli S et al (2006) Remodelling of the left ventricle in athlete\u2019s heart: a three dimensional echocardiographic and magnetic resonance imaging study. Heart 92(7):975\u2013976","journal-title":"Heart"},{"issue":"10","key":"8_CR79","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 15(10):1063\u20131093","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"8_CR80","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1540-8175.2007.00587.x","volume":"25","author":"S Castro De","year":"2008","unstructured":"De Castro S, Cavarretta E, Milan A et al (2008) Usefulness of tricuspid annular velocity in identifying global RV dysfunction in patients with primary pulmonary hypertension: a comparison with 3D echo-derived right ventricular ejection fraction. Echocardiography 25(3):289\u2013293","journal-title":"Echocardiography"},{"issue":"7","key":"8_CR81","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.amjcard.2013.05.038","volume":"112","author":"M Lotrionte","year":"2013","unstructured":"Lotrionte M, Cavarretta E, Abbate A et al (2013) Temporal changes in standard and tissue Doppler imaging echocardiographic parameters after anthracycline chemotherapy in women with breast cancer. Am J Cardiol 112(7):1005\u20131012","journal-title":"Am J Cardiol"},{"issue":"5","key":"8_CR82","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","volume":"5","author":"H Sawaya","year":"2012","unstructured":"Sawaya H, Sebag IA, Plana JC et al (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5(5):596\u2013603","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"8_CR83","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/CIRCIMAGING.113.000899","volume":"6","author":"P Thavendiranathan","year":"2013","unstructured":"Thavendiranathan P, Wintersperger BJ, Flamm SD et al (2013) Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging 6(6):1080\u20131091","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"8_CR84","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004","journal-title":"N Engl J Med"},{"issue":"14","key":"8_CR85","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","volume":"361","author":"AJ Moss","year":"2009","unstructured":"Moss AJ, Hall WJ, Cannom DS et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361(14):1329\u20131338","journal-title":"N Engl J Med"},{"issue":"3","key":"8_CR86","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jacc.2013.09.040","volume":"63","author":"GH Oliveira","year":"2014","unstructured":"Oliveira GH, Dupont M, Naftel D et al (2014) Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 63(3):240\u2013248","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"8_CR87","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1751-7133.2012.00291.x","volume":"18","author":"JM Appel","year":"2012","unstructured":"Appel JM, Sander K, Hansen PB et al (2012) Left ventricular assist device as bridge to recovery for anthracycline-induced terminal heart failure. Congest Heart Fail 18(5):291\u2013294","journal-title":"Congest Heart Fail"},{"issue":"7","key":"8_CR88","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1249\/MSS.0b013e3181e0c112","volume":"42","author":"KH Schmitz","year":"2010","unstructured":"Schmitz KH, Courneya KS, Matthews C et al (2010) American College of Sports Medicine. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42(7):1409\u20131426","journal-title":"Med Sci Sports Exerc"},{"issue":"4","key":"8_CR89","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.soncn.2007.08.002","volume":"23","author":"KS Courneya","year":"2007","unstructured":"Courneya KS, Friedenreich CM (2007) Physical activity and cancer control. Semin Oncol Nurs 23(4):242\u2013252","journal-title":"Semin Oncol Nurs"},{"issue":"12","key":"8_CR90","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1519\/JSC.0b013e31825bb594","volume":"26","author":"F Sanchis-Gomar","year":"2012","unstructured":"Sanchis-Gomar F, Garcia-Gimenez JL, Perez-Quilis C et al (2012) Physical exercise as an epigenetic modulator: eustress, the \u201cpositive stress\u201d as an effector of gene expression. J Strength Cond Res 26(12):3469\u20133472","journal-title":"J Strength Cond Res"},{"issue":"6","key":"8_CR91","first-page":"580","volume":"27","author":"D Lemanne","year":"2013","unstructured":"Lemanne D, Cassileth B, Gubili J (2013) The role of physical activity in cancer prevention, treatment, recovery, and survivorship. Oncology 27(6):580\u2013585","journal-title":"Oncology"},{"issue":"29","key":"8_CR92","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S et al (2016) 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J 37(29):2315\u20132381","journal-title":"Eur Heart J"},{"key":"8_CR93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-642-04231-7_2","volume":"186","author":"BM Lynch","year":"2011","unstructured":"Lynch BM, Neilson HK, Friedenreich CM (2011) Physical activity and breast cancer prevention. Recent Results Cancer Res 186:13\u201342","journal-title":"Recent Results Cancer Res"},{"issue":"4","key":"8_CR94","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/bjc.2013.37","volume":"108","author":"G Behrens","year":"2013","unstructured":"Behrens G, Leitzmann MF (2013) The association between physical activity and renal cancer: systematic review and meta-analysis. Br J Cancer 108(4):798\u2013811","journal-title":"Br J Cancer"},{"issue":"20","key":"8_CR95","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/jnci\/djs354","volume":"104","author":"T Boyle","year":"2012","unstructured":"Boyle T, Keegel T, Bull F et al (2012) Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst 104(20):1548\u20131561","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"8_CR96","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/aje\/kws280","volume":"177","author":"CC Simons","year":"2013","unstructured":"Simons CC, Hughes LA, van Engeland M et al (2013) Physical activity, occupational sitting time, and colorectal cancer risk in the Netherlands cohort study. Am J Epidemiol 177(6):514\u2013530","journal-title":"Am J Epidemiol"},{"issue":"9","key":"8_CR97","doi-asserted-by":"crossref","first-page":"e73753","DOI":"10.1371\/journal.pone.0073753","volume":"8","author":"E Stamatakis","year":"2013","unstructured":"Stamatakis E, Chau JY, Pedisic Z et al (2013) Are sitting occupations associated with increased all-cause, cancer, and cardiovascular disease mortality risk? A pooled analysis of seven British population cohorts. PLoS One 8(9):e73753","journal-title":"PLoS One"},{"key":"8_CR98","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5868-10-20","volume":"10","author":"ES George","year":"2013","unstructured":"George ES, Rosenkranz RR, Kolt GS (2013) Chronic disease and sitting time in middle-aged Australian males: findings from the 45 and Up Study. Int J Behav Nutr Phys Act 10:20","journal-title":"Int J Behav Nutr Phys Act"},{"issue":"1","key":"8_CR99","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12894-016-0168-0","volume":"16","author":"E Angenete","year":"2016","unstructured":"Angenete E, Anger\u00e5s U, B\u00f6rjesson M et al (2016) Physical activity before radical prostatectomy reduces sick leave after surgery\u00a0\u2013 results from a prospective, non-randomized controlled clinical trial (LAPPRO). BMC Urol 16(1):50","journal-title":"BMC Urol"},{"issue":"5","key":"8_CR100","first-page":"683","volume":"16","author":"ML Winningham","year":"1989","unstructured":"Winningham ML, MacVicar MG, Bondoc M et al (1989) Effect of aerobic exercise on body weight and composition in patients with breast cancer on adjuvant chemotherapy. Oncol Nurs Forum 16(5):683\u2013689","journal-title":"Oncol Nurs Forum"},{"issue":"6","key":"8_CR101","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/1534735414547108","volume":"13","author":"CP Repka","year":"2014","unstructured":"Repka CP, Peterson BM, Brown JM et al (2014) Cancer type does not affect exercise-mediated improvements in cardiorespiratory function and fatigue. Integr Cancer Ther 13(6):473\u2013481","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"8_CR102","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1534735407305871","volume":"6","author":"CM Schneider","year":"2007","unstructured":"Schneider CM, Hsieh CC, Sprod LK et al (2007) Exercise training manages cardiopulmonary function and fatigue during and following cancer treatment in male cancer survivors. Integr Cancer Ther 6(3):235\u2013241","journal-title":"Integr Cancer Ther"},{"key":"8_CR103","first-page":"CD008465","volume":"8","author":"SI Mishra","year":"2012","unstructured":"Mishra SI, Scherer RW, Snyder C et al (2012) Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 8:CD008465","journal-title":"Cochrane Database Syst Rev"},{"key":"8_CR104","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12916-015-0513-2","volume":"13","author":"CS Kampshoff","year":"2015","unstructured":"Kampshoff CS, Chinapaw MJ, Brug J et\u00a0al (2015) Randomized controlled trial of the effects of high intensity and low-to-moderate intensity exercise on physical fitness and fatigue in cancer survivors: results of the resistance and endurance exercise after chemotherapy (REACT) study. BMC Med 13:275","journal-title":"BMC Med"},{"issue":"6","key":"8_CR105","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/02640414.2010.545427","volume":"29","author":"JD Bartlett","year":"2011","unstructured":"Bartlett JD, Close GL, MacLaren DP et al (2011) High-intensity interval running is perceived to be more enjoyable than moderate-intensity continuous exercise: implications for exercise adherence. J Sports Sci 29(6):547\u2013553","journal-title":"J Sports Sci"},{"issue":"3","key":"8_CR106","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1188\/12.CJON.293-300","volume":"16","author":"TA Albrecht","year":"2012","unstructured":"Albrecht TA, Taylor AG (2012) Physical activity in patients with advanced-stage cancer: a systematic review of the literature. Clin J Oncol Nurs 16(3):293\u2013300","journal-title":"Clin J Oncol Nurs"},{"issue":"1","key":"8_CR107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-015-1523-z","volume":"8","author":"W Siemens","year":"2015","unstructured":"Siemens W, Wehrle A, Gaertner J et\u00a0al (2015) Implementing a home-based exercise program for patients with advanced, incurable diseases after discharge and their caregivers: lessons we have learned. BMC Res Notes 8(1):1\u20136","journal-title":"BMC Res Notes"},{"issue":"3","key":"8_CR108","doi-asserted-by":"crossref","first-page":"554","DOI":"10.5306\/wjco.v5.i3.554","volume":"5","author":"S Eyigor","year":"2014","unstructured":"Eyigor S, Akdeniz S (2014) Is exercise ignored in palliative cancer patients? World J Clin Oncol 5(3):554\u2013559","journal-title":"World J Clin Oncol"},{"issue":"1\u20132","key":"8_CR109","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/mgme.2000.3043","volume":"71","author":"MS Horenstein","year":"2000","unstructured":"Horenstein MS, Vander Heide RS, L\u2019Ecuyer TJ (2000) Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 71(1\u20132):436\u2013444","journal-title":"Mol Genet Metab"},{"issue":"1","key":"8_CR110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","volume":"61","author":"T Sim\u016fnek","year":"2009","unstructured":"Sim\u016fnek T, St\u00e9rba M, Popelov\u00e1 O et al (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61(1):154\u2013171","journal-title":"Pharmacol Rep"},{"issue":"8","key":"8_CR111","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0024-3205(00)00990-5","volume":"68","author":"MF Xu","year":"2001","unstructured":"Xu MF, Tang PL, Qian ZM et al (2001) Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 68(8):889\u2013901","journal-title":"Life Sci"},{"issue":"20","key":"8_CR112","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1161\/01.CIR.100.20.2100","volume":"100","author":"W Zhu","year":"1999","unstructured":"Zhu W, Zou Y, Aikawa R et al (1999) MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation 100(20):2100\u20132107","journal-title":"Circulation"},{"issue":"1","key":"8_CR113","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/cvr\/cvn076","volume":"79","author":"Y Yamamoto","year":"2008","unstructured":"Yamamoto Y, Hoshino Y, Ito T et al (2008) Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc Res 79(1):89\u201396","journal-title":"Cardiovasc Res"},{"issue":"1\u20132","key":"8_CR114","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11010-005-5905-8","volume":"273","author":"Y Shizukuda","year":"2005","unstructured":"Shizukuda Y, Matoba S, Mian OY et al (2005) Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem 273(1\u20132):25\u201332","journal-title":"Mol Cell Biochem"},{"issue":"18","key":"8_CR115","doi-asserted-by":"crossref","first-page":"13690","DOI":"10.1074\/jbc.275.18.13690","volume":"275","author":"YJ Kang","year":"2000","unstructured":"Kang YJ, Zhou ZX, Wang GW et al (2000) Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 275(18):13690\u201313698","journal-title":"J Biol Chem"},{"issue":"6","key":"8_CR116","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1172\/JCI115241","volume":"87","author":"EC Keung","year":"1991","unstructured":"Keung EC, Toll L, Ellis M et al (1991) L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations. J Clin Invest 87(6):2108\u20132113","journal-title":"J Clin Invest"},{"issue":"20","key":"8_CR117","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/S0024-3205(02)01524-2","volume":"70","author":"K Saeki","year":"2002","unstructured":"Saeki K, Obi I, Ogiku N et al (2002) Doxorubicin directly binds to the cardiac-type ryanodine receptor. Life Sci 70(20):2377\u20132389","journal-title":"Life Sci"},{"issue":"6 Suppl","key":"8_CR118","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1054\/jcaf.2002.129276","volume":"8","author":"MM Lewinter","year":"2002","unstructured":"Lewinter MM, Vanburen P (2002) Myofilament remodeling during the progression of heart failure. J Card Fail 8(6 Suppl):S271\u2013S275","journal-title":"J Card Fail"},{"issue":"2","key":"8_CR119","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/mol.63.2.368","volume":"63","author":"Y Kim","year":"2003","unstructured":"Kim Y, Ma AG, Kitta K et al (2003) Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 63(2):368\u2013377","journal-title":"Mol Pharmacol"},{"issue":"5","key":"8_CR120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0022-2828(77)80004-7","volume":"9","author":"MW Seraydarian","year":"1977","unstructured":"Seraydarian MW, Artaza L, Goodman MF (1977) Adriamycin: effect on mammalian cardiac cells in culture I. Cell population and energy metabolism. J Mol Cell Cardiol 9(5):375\u2013382","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"8_CR121","first-page":"395","volume":"23","author":"AB Combs","year":"1979","unstructured":"Combs AB, Hudman SL, Bonner HW (1979) Effect of exercise stress upon the acute toxicity of adriamycin in mice. Res Commun Chem Pathol Pharmacol 23(2):395\u2013398","journal-title":"Res Commun Chem Pathol Pharmacol"},{"issue":"4","key":"8_CR122","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1152\/jappl.1985.59.4.1298","volume":"59","author":"MM Kanter","year":"1985","unstructured":"Kanter MM, Hamlin RL, Unverferth DV et al (1985) Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin. J Appl Physiol (1985) 59(4):1298\u20131303","journal-title":"J Appl Physiol (1985)"},{"issue":"5","key":"8_CR123","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/0006-2952(94)90488-X","volume":"47","author":"LL Ji","year":"1994","unstructured":"Ji LL, Mitchell EW (1994) Effects of Adriamycin on heart mitochondrial function in rested and exercised rats. Biochem Pharmacol 47(5):877\u2013885","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"8_CR124","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijcard.2004.11.004","volume":"100","author":"A Ascens\u00e3o","year":"2005","unstructured":"Ascens\u00e3o A, Magalh\u00e3es J, Soares J et\u00a0al (2005) Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice. Int J Cardiol 100(3):451\u2013460","journal-title":"Int J Cardiol"},{"issue":"1","key":"8_CR125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijcard.2006.04.076","volume":"117","author":"A Ascens\u00e3o","year":"2007","unstructured":"Ascens\u00e3o A, Ferreira R, Magalh\u00e3es J (2007) Exercise-induced cardioprotection\u00a0\u2013 biochemical, morphological and functional evidence in whole tissue and isolated mitochondria. Int J Cardiol 117(1):16\u201330","journal-title":"Int J Cardiol"},{"issue":"6","key":"8_CR126","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2008.04.034","volume":"52","author":"C Werner","year":"2008","unstructured":"Werner C, Hanhoun M, Widmann T et al (2008) Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. J Am Coll Cardiol 52(6):470\u2013482","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"8_CR127","doi-asserted-by":"crossref","first-page":"R424","DOI":"10.1152\/ajpregu.00636.2004","volume":"289","author":"AJ Chicco","year":"2005","unstructured":"Chicco AJ, Schneider CM, Hayward R (2005) Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol 289(2):R424\u2013R431","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"8_CR128","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/01.fjc.0000199682.43448.2d","volume":"47","author":"AJ Chicco","year":"2006","unstructured":"Chicco AJ, Schneider CM, Hayward R (2006) Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol 47(2):182\u2013189","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"8_CR129","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1152\/japplphysiol.00148.2005","volume":"100","author":"AJ Chicco","year":"2006","unstructured":"Chicco AJ, Hydock DS, Schneider CM et al (2006) Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol (1985) 100(2):519\u2013527","journal-title":"J Appl Physiol (1985)"},{"issue":"5","key":"8_CR130","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1139\/cjpp-2013-0294","volume":"92","author":"TL Parry","year":"2014","unstructured":"Parry TL, Hydock DS, Jensen BT et al (2014) Endurance exercise attenuates cardiotoxicity induced by androgen deprivation and doxorubicin. Can J Physiol Pharmacol 92(5):356\u2013362","journal-title":"Can J Physiol Pharmacol"},{"issue":"8","key":"8_CR131","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.7314\/APJCP.2012.13.8.4025","volume":"13","author":"J Ashraf","year":"2012","unstructured":"Ashraf J, Roshan VD (2012) Is short-term exercise a therapeutic tool for improvement of cardioprotection against DOX-induced cardiotoxicity? An experimental controlled protocol in rats. Asian Pac J Cancer Prev 13(8):4025\u20134030","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"8_CR132","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.7314\/APJCP.2012.13.11.5849","volume":"13","author":"V Shirinbayan","year":"2012","unstructured":"Shirinbayan V, Roshan VD (2012) Pretreatment effect of running exercise on HSP70 and DOX-induced cardiotoxicity. Asian Pac J Cancer Prev 13(11):5849\u20135855","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"8_CR133","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/10641960802251891","volume":"30","author":"SC Kolwicz","year":"2008","unstructured":"Kolwicz SC, MacDonnell SM, Kendrick ZV et al (2008) Voluntary wheel running and pacing-induced dysfunction in hypertension. Clin Exp Hypertens 30(7):565\u2013573","journal-title":"Clin Exp Hypertens"},{"issue":"7","key":"8_CR134","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.cell.2010.11.036","volume":"143","author":"P Bostr\u00f6m","year":"2010","unstructured":"Bostr\u00f6m P, Mann N, Wu J et\u00a0al (2010) C\/EBP\u03b2 controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 143(7):1072\u20131083","journal-title":"Cell"},{"issue":"11","key":"8_CR135","first-page":"4401","volume":"29","author":"DS Hydock","year":"2009","unstructured":"Hydock DS, Wonders KY, Schneider CM et al (2009) Voluntary wheel running in rats receiving doxorubicin: effects on running activity and cardiac myosin heavy chain. Anticancer Res 29(11):4401\u20134407","journal-title":"Anticancer Res"},{"issue":"1","key":"8_CR136","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/1534735410392577","volume":"10","author":"DS Hydock","year":"2011","unstructured":"Hydock DS, Lien CY, Jensen BT et al (2011) Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity. Integr Cancer Ther 10(1):47\u201357","journal-title":"Integr Cancer Ther"},{"issue":"5","key":"8_CR137","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1249\/MSS.0b013e318163744a","volume":"40","author":"DS Hydock","year":"2008","unstructured":"Hydock DS, Lien CY, Schneider CM et al (2008) Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction. Med Sci Sports Exerc 40(5):808\u2013817","journal-title":"Med Sci Sports Exerc"},{"issue":"12","key":"8_CR138","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1258\/ebm.2012.012137","volume":"237","author":"DS Hydock","year":"2012","unstructured":"Hydock DS, Lien CY, Jensen BT et al (2012) Rehabilitative exercise in a rat model of doxorubicin cardiotoxicity. Exp Biol Med (Maywood) 237(12):1483\u20131492","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"8_CR139","doi-asserted-by":"crossref","first-page":"E629","DOI":"10.1152\/ajpendo.00171.2003","volume":"285","author":"DL Coven","year":"2003","unstructured":"Coven DL, Hu X, Cong L et al (2003) Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise. Am J Physiol Endocrinol Metab 285(3):E629\u2013E636","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"8_CR140","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1152\/japplphysiol.00924.2012","volume":"115","author":"AJ Smuder","year":"2013","unstructured":"Smuder AJ, Kavazis AN, Min K et al (2013) Doxorubicin-induced markers of myocardial autophagic signaling in sedentary and exercise trained animals. J Appl Physiol (1985) 115(2):176\u2013185","journal-title":"J Appl Physiol (1985)"},{"key":"8_CR141","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbacli.2016.06.001","volume":"6","author":"N Nair","year":"2016","unstructured":"Nair N, Gongora E (2016) Heart failure in chemotherapy-related cardiomyopathy: can exercise make a difference? BBA Clin 6:69\u201375","journal-title":"BBA Clin"},{"issue":"28","key":"8_CR142","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1200\/JCO.2006.08.2024","volume":"25","author":"KS Courneya","year":"2007","unstructured":"Courneya KS, Segal RJ, Mackey JR et al (2007) Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 25(28):4396\u20134404","journal-title":"J Clin Oncol"},{"issue":"23","key":"8_CR143","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/jnci\/djt297","volume":"105","author":"KS Courneya","year":"2013","unstructured":"Courneya KS, McKenzie DC, Mackey JR et al (2013) Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst 105(23):1821\u20131832","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"8_CR144","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10549-014-2883-0","volume":"144","author":"KS Courneya","year":"2014","unstructured":"Courneya KS, Segal RJ, Mackey JR et al (2014) Effects of exercise dose and type on sleep quality in breast cancer patients receiving chemotherapy: a multicenter randomized trial. Breast Cancer Res Treat 144(2):361\u2013369","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"8_CR145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/0284186X.2013.781673","volume":"53","author":"WE Hornsby","year":"2014","unstructured":"Hornsby WE, Douglas PS, West MJ et al (2014) Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. Acta Oncol 53(1):65\u201374","journal-title":"Acta Oncol"},{"issue":"3","key":"8_CR146","first-page":"319","volume":"49","author":"F Vincent","year":"2013","unstructured":"Vincent F, Labourey JL, Leobon S et al (2013) Effects of a home-based walking training program on cardiorespiratory fitness in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Eur J Phys Rehabil Med 49(3):319\u2013329","journal-title":"Eur J Phys Rehabil Med"},{"issue":"15","key":"8_CR147","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1158\/1078-0432.CCR-09-0628","volume":"15","author":"MJ Haykowsky","year":"2009","unstructured":"Haykowsky MJ, Mackey JR, Thompson RB et al (2009) Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res 15(15):4963\u20134967","journal-title":"Clin Cancer Res"},{"issue":"7","key":"8_CR148","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1249\/MSS.0b013e318213fefb","volume":"43","author":"CE Garber","year":"2011","unstructured":"Garber CE, Blissmer B, Deschenes MR et al (2011) American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 43(7):1334\u20131359","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"8_CR149","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1249\/MSS.0b013e31822cb5f2","volume":"44","author":"R Musanti","year":"2012","unstructured":"Musanti R (2012) A study of exercise modality and physical self-esteem in breast cancer survivors. Med Sci Sports Exerc 44(2):352\u2013361","journal-title":"Med Sci Sports Exerc"},{"issue":"5","key":"8_CR150","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/1055-9965.EPI-06-0870","volume":"16","author":"LW Jones","year":"2007","unstructured":"Jones LW, Haykowsky M, Peddle CJ et al (2007) Cardiovascular risk profile of patients with HER2\/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and\/or trastuzumab. Cancer Epidemiol Biomark Prev 16(5):1026\u20131031","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"8_CR151","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s11764-015-0437-z","volume":"9","author":"F Scharhag-Rosenberger","year":"2015","unstructured":"Scharhag-Rosenberger F, Kuehl R, Klassen O et al (2015) Exercise training intensity prescription in breast cancer survivors: validity of current practice and specific recommendations. J Cancer Surviv 9(4):612\u2013619","journal-title":"J Cancer Surviv"}],"updated-by":[{"DOI":"10.1007\/978-981-10-4304-8_20","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T00:00:00Z","timestamp":1514505600000}}],"container-title":["Advances in Experimental Medicine and Biology","Exercise for Cardiovascular Disease Prevention and Treatment"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-10-4304-8_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T09:59:10Z","timestamp":1570269550000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-10-4304-8_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9789811043031","9789811043048"],"references-count":151,"URL":"https:\/\/doi.org\/10.1007\/978-981-10-4304-8_8","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/978-981-10-4304-8_20","asserted-by":"object"}]},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}